Recursion

Recursion is an AI-native drug discovery company that operates at the intersection of high-throughput wet-lab biology and machine learning. Its core innovation is a massive, automated phenomics platform: robotic systems culture millions of cellular experiments in parallel, high-content imaging captures the resulting morphological changes, and deep learning decodes the relationships between genetic perturbations, chemical compounds, and disease states. Unlike many competitors that rely on public datasets, Recursion generates its own proprietary biological data at industrial scale, feeding foundation models such as Phenom-1 for cellular phenomics and MolE for molecular chemistry. These models are intended to predict therapeutic candidates, identify novel targets, and reveal mechanisms of action with far fewer traditional bench experiments than conventional drug discovery.

The company pursues a hybrid business model. It advances internally discovered drug candidates through preclinical and clinical stages while simultaneously licensing its capabilities to large pharmaceutical partners via the Recursion OS platform. Partnerships typically generate upfront fees, research funding, and milestone payments. With dual headquarters in Salt Lake City and Montreal, Recursion merges American wet-lab automation with Canadian deep-learning research. A strategic collaboration with Nvidia further amplifies its compute capacity, aiming to train large-scale biology foundation models that could become industry-standard infrastructure for target discovery.

Founded in 2013 with Canadian roots, Recursion began with the premise that mapping cellular biology at scale could systematically decode disease. The company’s early work focused on rare diseases, using automated microscopy and machine learning to identify therapeutic candidates from cellular phenotypes. Over time, the platform broadened to address larger indications, requiring exponential growth in wet-lab automation and computational infrastructure.

The company established its operational headquarters in Salt Lake City, where it built one of the world’s largest automated biological data factories, while simultaneously developing a major artificial intelligence research presence in Montreal. A defining inflection point came in 2021, when Recursion went public on the Nasdaq under the ticker RXRX, raising significant capital to expand its platform. In subsequent years, the company deepened its Canadian footprint through strategic acquisitions of AI-driven drug discovery firms, reinforcing the Montreal hub. Today, Recursion sits at the convergence of biotechnology and generative AI, though it has yet to bring a wholly owned drug to market.

Recursion occupies a distinct niche in the crowded AI drug-discovery landscape. While peers such as Exscientia, BenevolentAI, and Schrödinger emphasize computational chemistry, knowledge graphs, or physics-based modeling, Recursion’s moat is rooted in proprietary wet-lab data generation. Its massive archive of cellular images and phenomic readouts is difficult to replicate quickly, giving its foundation models a training data advantage that purely in-silico competitors lack. The Nvidia partnership further distinguishes it on the compute and model-scale frontier, potentially allowing it to build generalizable biology foundation models that others cannot afford to train.

However, this asset-heavy approach is a double-edged sword. The capital requirements for robotic labs, reagents, and cloud compute are enormous, creating a higher cash-burn profile than leaner software-only rivals. In clinical credibility, Recursion is still proving itself: it has fewer late-stage assets than some competitors and no approved drugs yet, meaning near-term revenue remains tied to partnership economics rather than product sales. If its internal pipeline produces positive clinical readouts or its Nvidia-backed models become licensable industry standards, Recursion could leapfrog competitors. Until then, it must balance platform investment against the long timelines of drug development.